Nexus Finance
SBIO.L Invesco NASDAQ Biotech UCITS ETF Acc | IE00BQ70R696

TER

0.4%

Total Expense Ratio per year

Fund Size

$472941.25B

Assets under management

Holdings

251

Underlying equities

Dividend Yield

0.00%

Accumulating

Performance Analysis

Based on selected timeframe (1D)

Top Performers - Upside

Oric Pharmaceuticals, Inc. ORIC
+11.11%
LENZ Therapeutics, Inc. LENZ
+8.51%
Silence Therapeutics PLC R XRP2.F
+8.11%

Top Performers - Downside

Codexis, Inc. CDXS
-25.63%
Zevra Therapeutics, Inc. ZVRA
-23.92%
Jyong Biotech Ltd. MENS
-12.92%

Top Contributors - Upside

Amgen Inc. AMGN • Weight: 7.62% • Perf: +1.22%
+0.09% Impact
Vertex Pharmaceuticals Incorpor VRTX • Weight: 7.83% • Perf: +0.90%
+0.07% Impact
Alnylam Pharmaceuticals, Inc. ALNY • Weight: 2.81% • Perf: +1.13%
+0.03% Impact

Top Contributors - Downside

Moderna, Inc. Weight: 2.04% • Perf: -5.17%
-0.11% Impact
Gilead Sciences, Inc. Weight: 7.08% • Perf: -1.18%
-0.08% Impact
Summit Therapeutics Inc. Weight: 0.81% • Perf: -8.81%
-0.07% Impact

ETF Profile

Provider Invesco
Region N/A
Country US
Sector Health Care
Strategy N/A
Theme Biotech
Distribution Policy Accumulating
Replication Swap based Unfunded
Sustainable No

Aggregate Fundamentals

Weighted average of underlying holdings

Avg P/E Ratio 23.57
Avg Forward P/E 58.08

Growth Analysis

EPS Growth (LY->CY) -272.33%
Revenue Growth (LY->CY) +61.94%
EPS Growth (CY->NY) +137.64%
Revenue Growth (CY->NY) +365.86%
ende